AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

To join this study, you need to be at least 12 years old. You must have B-cell Acute Lymphoblastic Leukaemia (B-ALL) where the cancer cells show a specific marker called CD19. Your bone marrow (the spongy tissue inside bones where blood cells are made) must have at least 5% cancer cells.

Importantly, your cancer must have either come back or not responded well after at least two previous treatments. If there are no other standard treatments available, you might still be considered after just one previous treatment. If you have a specific type of B-ALL called Philadelphia positive, you can join if you haven't been able to tolerate or respond to certain other medicines (TKIs).

There are also some reasons why you might not be able to join. For example, if the cancer has spread to your brain or spinal fluid, or if you have certain other serious medical conditions affecting your brain or nervous system. Other reasons include recent severe side effects from past treatments, recent stem cell transplants, or specific types of cancer spread like to the testicles. Your doctor will carefully check all the details to see if this study is suitable for you.

This study is looking at a new medicine called AZD0486. Taking part would involve receiving this medicine. Since it's a new treatment being tested, there will be careful monitoring of your health. This will include regular visits to the hospital or clinic for check-ups, blood tests, and other procedures to see how you are responding to the medicine and to check for any side effects. The study has different parts: first, finding the right dose ('dose escalation'), then fine-tuning it ('dose optimisation'), and finally, expanding the study to more people at the best dose ('dose expansion'). The total duration of your participation, and the exact schedule of visits and tests, will be explained in detail by the study team.